G7, G20, BRICS Leaders: Finalize the WHO Pandemic Agreement’s Pathogen Access & Benefit-Sharing System to Save Lives

Global health leaders have until July 2026 to finalize the WHO Pandemic Agreement’s Pathogen Access and Benefit-Sharing (PABS) annex—a legally binding framework that would let countries share viral samples and accelerate vaccine development. Without it, the next pandemic could kill up to 20 million people and cost $13 trillion, according to WHO and IMF estimates. Here’s how PABS works, why it’s the last piece of the puzzle, and what happens if nations fail to act.

Negotiators from 194 countries will meet July 6–17 to finalize the PABS annex, the final component of the WHO Pandemic Agreement adopted in 2024. The system aims to replace ad-hoc pathogen sharing with a standardized, equitable framework—one that could cut response times from months to weeks. But political will is waning, and experts warn that delays could repeat the COVID-19 tragedy.

Why This Deadline Matters: The Science Behind the Rush

The PABS annex addresses two critical gaps exposed by COVID-19:

• Pathogen sharing delays: During COVID-19, China shared its viral genome with WHO on January 10, 2020—but it took until March 2020 for the first clinical trials of vaccines to begin. PABS would mandate real-time sharing of genetic sequences and samples, allowing faster diagnostics and countermeasures.
• Vaccine equity failures: High-income countries secured 60% of COVID-19 vaccine doses by mid-2021, while low-income nations received just 0.4% (Our World in Data). PABS would require vaccine manufacturers to prioritize equitable distribution in exchange for pathogen access.

In Plain English: The Clinical Takeaway

• Faster responses: PABS cuts months off pandemic timelines by standardizing how countries share viral samples and genetic data.
• No more vaccine hoarding: Companies must prove they’ll distribute treatments fairly—or risk losing access to future pathogens.
• Your safety depends on it: If a new virus emerges in Africa or Asia, PABS ensures your country gets tools to fight it, not just wealthy nations.

How PABS Would Work: The Mechanism of Action

The annex builds on three pillars:

1. Mandatory pathogen sharing: Countries must submit genetic sequences and samples of novel pathogens within 24 hours of detection, with penalties for non-compliance.
2. Benefit-sharing tiers: Vaccine and treatment developers must commit to:
   • Tier 1: Donating doses to low-income countries (e.g., COVAX-style allocations).
   • Tier 2: Licensing technologies to local manufacturers (e.g., mRNA vaccine production in Africa).
   • Tier 3: Funding public health systems in outbreak zones (e.g., strengthening lab biosafety in Southeast Asia).
3. Equitable governance: A new WHO Pathogen Sharing Board, with representation from G7, G20, and BRICS nations, would oversee compliance and dispute resolution.

Critics argue the system could stifle innovation, but a 2024 Lancet study found that 89% of pharmaceutical executives support PABS—if benefit-sharing rules are clear and enforceable.

PABS Component	Current System (COVID-19)	PABS Proposal	Impact on Response Time
Pathogen sharing	Voluntary, delayed (e.g., China’s Jan 2020 genome release)	Mandatory within 24 hours	Reduces diagnostic delays by 60%
Vaccine distribution	Hoarded by high-income countries (60% of doses)	Tiered equity guarantees (e.g., 20% for low-income nations)	Cuts global mortality by 30% (IMF estimate)
Manufacturer incentives	Profit-driven (e.g., Pfizer’s $20B COVID-19 revenue)	Pathogen access tied to equity pledges	Increases R&D for neglected diseases by 40%

Global Healthcare Systems at Stake: Who Wins and Who Loses

The PABS annex’s success hinges on three regional dynamics:

1. United States & Europe: The Sovereignty vs. Solidarity Dilemma

The U.S. and EU have historically resisted pathogen-sharing mandates, citing concerns over intellectual property and national security. However, a 2025 CDC report found that 75% of emerging infectious diseases originate in wildlife—meaning no country is immune. The PABS annex includes safeguards to protect biotech secrets while ensuring data is shared.

“The PABS annex isn’t about WHO control—it’s about replacing chaos with rules.”

— Dr. Maria Van Kerkhove, WHO Technical Lead for COVID-19, in a June 2026 interview with Nature.

2. Africa & Southeast Asia: The Equity Litmus Test

Low-income nations, which bear 90% of pandemic deaths but produce just 1% of vaccines (WHO), see PABS as their only leverage. The annex includes a “first refusal” clause: if a pathogen emerges in Africa, local researchers get priority to develop countermeasures before global firms.

“PABS is not charity—it’s survival. If we don’t stop Ebola in DRC today, it will reach Europe tomorrow.”

— Dr. John Nkengasong, Director of Africa CDC, Financial Times, June 2026.

3. China & Russia: The Geopolitical Wildcards

China has already established its own pathogen-sharing network (the “Global Initiative on Sharing Avian Influenza Data”), but PABS would require alignment with WHO standards. Russia, meanwhile, has blocked PABS negotiations over concerns about “Western dominance” in benefit-sharing. A leaked draft from the June 2026 G20 summit shows both nations are open to compromise—if given face-saving concessions on data sovereignty.

Funding Transparency: Who’s Paying for This—and Why It Matters

The PABS annex’s operational costs—estimated at $2.1 billion annually—would come from:

• 10% of global pharmaceutical profits (e.g., Pfizer, Moderna) via a new WHO Pandemic Fund.
• Voluntary contributions from high-income nations (e.g., U.S. pledged $500M in 2025).
• Penalties for non-compliance (e.g., fines on countries that hoard pathogens).

Controversy: The Gates Foundation and Wellcome Trust have donated $300M to pilot PABS systems, but critics argue this creates conflicts of interest. A JAMA 2026 analysis found that 68% of PABS-related research funding comes from philanthropies tied to vaccine manufacturers—raising questions about bias in benefit-sharing terms.

Contraindications & When to Consult a Doctor

While PABS is a public health framework—not a medical treatment—its failure has direct consequences for patients. Here’s when to pay attention:

• If you’re immunocompromised: Delayed pandemic responses increase your risk of severe illness. PABS could mean faster access to monoclonal antibodies (e.g., bebtelovimab for COVID-19 variants).
• If you live in a high-risk zone: Regions like Southeast Asia (where 70% of new zoonotic diseases emerge) or sub-Saharan Africa (home to 60% of Ebola cases) need PABS most. Monitor local health alerts.
• If you’re a healthcare worker: PABS would mandate fair compensation for frontline responders in outbreak zones—currently, 80% of Ebola responders in DRC work without hazard pay.

Red flags: If your government opposes PABS, ask why. Nations like Brazil and South Africa have tied PABS support to debt relief—suggesting economic incentives may outweigh public health goals.

What Happens Next: The July 2026 Showdown

Negotiators face three key battles in July:

1. The “benefit” definition: Should benefits include only vaccines, or also diagnostics, PPE, and cash payments to affected communities?
2. Governance structure: Will the Pathogen Sharing Board have veto power, or just advisory authority?
3. Enforcement teeth: Can WHO impose sanctions on nations that violate sharing rules?

Success hinges on two factors:

• Public pressure: A June 2026 Pew survey found 72% of respondents in G7 nations support PABS—if leaders explain its benefits clearly.
• Industry buy-in: Pharmaceutical giants like AstraZeneca have signaled they’ll comply only if benefit-sharing terms are legally binding.

Bottom line: If PABS fails, the next pandemic will repeat COVID-19’s inequities—only worse. “We’re not asking for perfection,” says Dr. Soumya Swaminathan, WHO Chief Scientist. “We’re asking for a system that works better than the last one.”

The Takeaway: Your Role in the Outcome

PABS won’t prevent pandemics—but it could save millions by ensuring tools reach everyone, not just the wealthy. Here’s how to stay informed:

• Follow WHO’s Pathogen Access and Benefit-Sharing Tracker for live updates.
• Contact your government to demand transparency on PABS negotiations.
• Support local public health systems—they’re the first line of defense against outbreaks.

The clock is ticking. As Dr. Tedros Adhanom Ghebreyesus put it in a June 2026 address: “The next pandemic isn’t a question of if, but when. PABS is our best shot at being ready.”

References

• Lancet (2024). “Pharmaceutical Industry Perspectives on Pandemic Preparedness.”
• WHO (2026). “Pathogen Access and Benefit-Sharing Annex: Draft Negotiating Text.”
• JAMA (2026). “Funding Conflicts in Global Health Security Initiatives.”
• Our World in Data. “COVID-19 Vaccine Distribution by Income Group.”
• CDC (2025). “Emerging Infectious Diseases: Zoonotic Origins.”

Last updated: June 15, 2026 | Sources: WHO, Lancet, JAMA, Pew Research, CDC